GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermata Therapeutics Inc (NAS:DRMA) » Definitions » PB Ratio

Dermata Therapeutics (Dermata Therapeutics) PB Ratio : 0.39 (As of May. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Dermata Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-25), Dermata Therapeutics's share price is $3.38. Dermata Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $8.58. Hence, Dermata Therapeutics's PB Ratio of today is 0.39.

The historical rank and industry rank for Dermata Therapeutics's PB Ratio or its related term are showing as below:

DRMA' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 66.28
Current: 0.41

During the past 5 years, Dermata Therapeutics's highest PB Ratio was 66.28. The lowest was 0.00. And the median was 0.00.

DRMA's PB Ratio is ranked better than
94.75% of 1314 companies
in the Biotechnology industry
Industry Median: 2.51 vs DRMA: 0.41

During the past 12 months, Dermata Therapeutics's average Book Value Per Share Growth Rate was -83.10% per year.

Back to Basics: PB Ratio


Dermata Therapeutics PB Ratio Historical Data

The historical data trend for Dermata Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermata Therapeutics PB Ratio Chart

Dermata Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
- - 1.43 0.84 0.38

Dermata Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.66 0.53 0.38 0.72

Competitive Comparison of Dermata Therapeutics's PB Ratio

For the Biotechnology subindustry, Dermata Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermata Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermata Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Dermata Therapeutics's PB Ratio falls into.



Dermata Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Dermata Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=3.38/8.575
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Dermata Therapeutics  (NAS:DRMA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Dermata Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Dermata Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermata Therapeutics (Dermata Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3525 Del Mar Heights Road, Suite No. 322, San Diego, CA, USA, 92130
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
Executives
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Gerald T Proehl 10 percent owner, officer: Pres., CEO and Chairman
Van Hoose Kyri K. officer: Chief Financial Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Mary Fisher director C/O ACORDA THERAPEUTICS, INC., 15 SKYLINE DRIVE, HAWTHORNE NY 10532
David F Hale director 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Wendell Wierenga director C/O CIPHERGEN BIOSYSTEMS INC, 6611 DUMBARTON CIRCLE, FREMONT CA 94555
Kathleen D. Scott director C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Thomas Insley officer: Chief Financial Officer SKINMEDICA, INC., 5909 SEA LION PLACE, SUITE H, CARLSBAD CA 92010
Bedoya-toro Munera Maria E officer: Senior VP 10590 WEST OCEAN AIR DRIVE, SUITE 200, SAN DIEGO CA 92130
Andrew Seth Sandler director 1301 2ND AVE, SEATTLE WA 98101
Christopher J. Nardo officer: Senior VP, Development C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
Proehl Investment Ventures Llc 10 percent owner C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #332, SAN DIEGO CA 92130

Dermata Therapeutics (Dermata Therapeutics) Headlines